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Abstract
Background: Although nonsustained ventricular tachycardia (NSVT) is a risk factor
for sudden cardiac death in hypertrophic-cardiomyopathy (HCM), the impact of pre-
mature ventricular contraction (PVC) burden, in the absence of NSVT, is not well-
known.
Hypothesis: PVC burden may be associated with myocardial fibrosis and genetic
mutations in patients with HCM.
Methods: Of the 212 patients prospectively enrolled to the HCM registry of genet-
ics, 84 were evaluated with both cardiac magnetic resonance, 24-hour Holter moni-
toring and genetic analysis. Among them, 71 patients have not been diagnosed
with NSVT.
Results: Patients with NSVT (n = 13) had a higher late gadolinium enhancement
(LGE) amount, extracellular volume fraction (ECV), and prevalence of sarcomere
mutations compared with patients without NSVT. Among patients without NSVT,
those with LGE (n = 46) had a higher total PVC (109 ± 332 vs 7 ± 13, P = .003) and
PVC burden (0.114 ± 0.225 vs 0.008 ± 0.014%, P = .003) during 24-hour Holter mon-
itoring compared with others. The %LGE and global ECV were correlated with PVC
burden (r = 0.377, P = .001; r = 0.401, P = .001). The optimal cutoff value for PVC
number for LGE was 45 (37.0% and 100% sensitivity and specificity, respectively)
with 0.733 of the area under the receiver operating characteristic-curve (P < .001).
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Thick filament gene mutation was more prevalent in the higher PVC burden group
(41.2% vs 16.7%, P = .048).
Conclusion: Total PVC burden is significantly related to increase in myocardial fibro-
sis in HCM patients without NSVT.
K E YWORD S
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1 | INTRODUCTION
Late gadolinium enhancement (LGE) represents myocardial fibro-
sis and is a well-known sudden cardiac death (SCD) predictor in
hypertrophic-cardiomyopathy (HCM).1 Current guidelines sug-
gest the presence of nonsustained ventricular tachycardia (NSVT)
as a risk factor for SCD in patients with HCM.2,3 However, there
are some cases that NSVT is not detected in a 24 to 48 hour
Holter monitoring, a recommendation of the current guidelines. A
fibrotic myocardium could trigger and act as a substrate for both
premature ventricular contraction (PVC) and NSVT.4 High-PVC
burden may reflect myocardial fibrosis even in the absence of
NSVT. Moreover, sarcomere-associated gene mutations have
been associated with ventricular arrhythmia.5 We investigated
(1) the association between NSVT and myocardial fibrotic burden,
(2) the association between PVC burden and myocardial fibrotic
burden in HCM patients without NSVT, and (3) contribution of
sarcomere-associated mutations for NSVT and PVC burden in a
24-hour Holter monitoring.
2 | METHODS
2.1 | Study population
A total of 432 patients were enrolled in the HCM registry from 2006
to 2014 at our hospital. After excluding those patients who discon-
tinued follow-ups, were unable to visit the clinic due to migration or
death, or were denied participation in the study, 212 patients were
consecutively enrolled and underwent genetic testing. Of the
212 patients prospectively enrolled to the HCM registry of
genetics,6 84 were evaluated with both cardiac magnetic resonance
and 24-hour Holter monitoring. Among them, 71 patients (58 males,
mean age: 71 ± 13 years) have not been diagnosed with NSVT. We
divided the patients into two groups according to the presence of
NSVT (NSVT group vs no NSVT group), then further divided the
patients of “no NSVT group” into higher PVC burden group and
lower PVC burden group according to the burden of PVC. The study
protocol conforms to the ethical guidelines of the 1975 Declaration
of Helsinki and was approved by our Institutional Review Board
(3-2015-0019). A written informed consent was obtained for each
subject.
2.2 | 24-hour Holter monitoring analysis
A 24-hour Holter monitoring was performed with SEER light
(GE Healthcare) machine and was analyzed by both manual and automatic
reviews of all 24-hour echocardiography (ECGs). NSVT was defined as an
episode of ventricular tachycardia (VT) with a heart rate of at least
120 beats per minute, lasting for at least three beats and persisting less
than 30 seconds. Total PVC number was calculated, and two PVCs in a
row were defined as couplet. PVC burden was defined as percent of total
PVC number divided by total beats during monitoring.
2.3 | Conventional echocardiography
A routine standard echocardiography study was performed to mea-
sure the systolic and diastolic parameters according to the current
American Society of Echocardiography guidelines.7 Continuous wave
Doppler was used to measure peak velocity across the LV outflow
tract (LVOT), and the pressure gradient was calculated using the
Bernoulli equation as follows: 4x (peak velocity across the LVOT).. It
was measured at resting and during Valsalva maneuver. LVOT
obstruction was defined as a systolic pressure gradient ≥30 mmHg.
Details are described in Supplementary Method S1.
2.4 | Cardiac magnetic resonance imaging
Cardiac magnetic resonance (CMR) imaging was performed using a
1.5-T scanner (Magnetom Avanto; Siemens Medical Solutions,
Erlangen, Germany) with a phased array body coil. We analyzed LGE,
T1, and extracellular volume fraction (ECV) for presenting myocardial
fibrosis. The presence of LGE involvement in each segment and the
total number of LGE-involving segments was measured. Native T1
mapping with the modified Look-Locker technique was performed
during the mid-diastolic phase, and post-T1 mapping was performed
15 minutes after contrast media injection using the same slice axis
and parameters as the pre-T1 mapping. The percentage of LGE in LV
mass was measured using dedicated quantitative analysis software
(QmassMR 7.5 or 8.1, Medis, Leiden, Netherland) on LGE images with
phase-sensitive inversion recovery (PSIR). To improve the reproduc-
ibility, a radiologist and a cardiologist, both with more than 10 years
of experience analyzed the LGE sizes. Boundaries of contrast-enhanced
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areas were automatically traced in each short-axis slice image. On LGE-
CMR images, the myocardium with an abnormal enhancement was defined
as an area of hyperenhancement of more than five standard deviations
from the remote myocardium. Remote myocardium was defined as non-
enhanced myocardium, which is the opposite of hyperenhanced myocar-
dium. Maximal signal was determined by computer-assisted window
thresholding of the enhanced area. Obvious artifacts, such as those caused
by motion, were excluded using a tool from the software package. Total
LGE volume was calculated by summing the LGE volumes of all the slices.8
Using the QMap RE (Medis, Leiden, Netherland), native T1, post-T1, and
ECV analyses were performed. The myocardial ECV was automatically cal-
culated with the following equation:
ECV = (ΔR1 of myocardium∕ΔR1 of LV blood pool) × (1
−hematocrit),
where R1 = 1∕T1 and ΔR1 = postcontrast R1−precontrast R1.9
The LGE, T1, and ECV values were measured according to the
American Heart Association (AHA) 16-segment model. Currently LGE,
reflecting replacement fibrosis, is the most widely proven prognostic
marker of SCD in HCM, therefore we chose LGE as a targeted value
to determine the cutoff value of PVC burden.
2.5 | Genetic analysis
2.5.1 | HCM gene panel design, DNA preparation,
and data-analysis of the HCM gene panel
A literature search of the PubMed database was performed for
targeted gene selection for the comprehensive HCM-specific panel. It
included 82 genes (33 sarcomere-associated protein genes, 5 pheno-
copy genes, and 44 nuclear genes linked to mitochondrial cardiomyopa-
thy).6 The HCM genes consisted of 8 validated sarcomere genes and
25 putative HCM genes.10 We divided the sarcomere genes into two
subgroups: thick filament genes (MYH7, MYBPC3, MYH6, and MYL3)
and thin filament genes (other sarcomere genes except for thick fila-
ment genes). The details are described in Supplementary Method S2.
2.6 | Statistical analysis
Continuous variables with normal distributions are reported as the
mean ± SD or 95% confidence interval. The Student t tests were used
to compare the means of the continuous variables that were approxi-
mately normally distributed between the two groups. Normality was
determined using the Shapiro-Wilk test. Categorical variables were
reported as counts (or percentages) and were compared using the χ2
tests. For the reproducibility test, paired sample t-tests were per-
formed and Pearson's correlation coefficients were calculated.
Receiver operating characteristic (ROC) analysis was performed to
identify the optimal cutoff values of burden of PVC for the presence
of LGE. All clinical statistical analyses were performed using the SPSS
version 25.0 statistical package (IBM Corp., Armonk, NewYork). A
two-sided P-value <.05 was considered to be statistically significant.
3 | RESULTS
3.1 | Genetic, structural, and functional
characteristics between patients with and
without NSVT
We compared the baseline characteristics between patients with NSVT
(n = 13) and without NSVT (n = 71) (Table 1). Patients with NSVT had
more prevalent pathogenic or likely pathogenic sarcomere-associated
mutations (69.2% vs 26.8%, P = .005) and variants of uncertain signifi-
cance (VUS) of sarcomere-associated gene (84.6% vs 50.7%, P = .032).
PVC couplet was more prevalent in the NSVT group compared with
the no NSVT group (61.5% vs 21.4%, P = .006). In the echocardio-
graphic analysis, the NSVT group had higher maximal wall thickness
(22.3 ± 4.2 vs 18.9 ± 3.8 mm, P = .004), higher LV end-systolic volume
(31.8 ± 11.2 vs 24.3 ± 10.0 mL, P = .017), and lower LV ejection frac-
tion (60.5 ± 9.3 vs 65.0 ± 5.7%, P = .023), e0 (4.3 ± 1.7 vs 5.4 ± 1.8 cm/
s, P = .038), a0 (6.0 ± 1.5 vs 8.0 ± 1.7 cm/s, P = .001), and s0 (5.5 ± 1.6
vs 7.2 ± 1.7 cm/s, P = .001) compared with the no NSVT group. In the
CMR analysis, the NSVT group had higher %LGE amount of LV (15.3
± 13.2 vs 7.0 ± 8.3%, P = .004), higher number of LGE segments (5.9
± 3.5 vs 3.1 ± 3.1, P = .003), and higher LV mass index (102.8 ± 24.0 vs
85.4 ± 25.3 g/m2, P = .024) compared with the no NSVT group.
3.2 | PVC burden and genetics according to the
presence of LGE in patients without NSVT
We analyzed the characteristics of the patients without NSVT (n = 71).
Baseline characteristics between these two groups according to the
presence of LGE are compared in Supplemental Table S1. Patients with
LGE had more prevalent sarcomere-associated gene mutation (37.0%
vs 8.0%, P = .011), thicker filament gene mutation (30.4% vs 8.0%,
P = .039), and higher total beats (109 ± 332 vs 7 ± 13 beats per day,
P = .003), PVC burden (0.114 ± 0.225 vs 0.008 ± 0.014%, P = .003)
during a 24-hour Holter monitoring compared with patients without
LGE. In the echocardiographic analysis, patients with LGE had a lower
a0 (7.7 ± 1.4 vs 8.6 ± 2.1 cm/s, P = .041) compared with patients with-
out LGE. In the CMR analysis, the NSVT group had a lower post-T1
(593.51 ± 56.93 vs 636.97 ± 66.29 ms, P = .006) and higher ECV
(33.48 ± 4.80 vs 29.49 ± 3.89 ms, P = .001), LV mass (167.55 ± 52.90
vs 133.00 ± 40.96 g, P = .006), and LV mass index (92.45 ± 25.67 vs
72.29 ± 18.94 g/m2, P < .001) compared with patients without LGE.
3.3 | Association between PVC and myocardial
extracellular space expansion
The %LGE was correlated with total PVC beats (r = 0.358, P = .002)
and PVC burden (r = 0.377, P = .001) of the 24-hour Holter monitor-
ing. Furthermore, E/e0 was correlated with %LGE (r = 0.263, P = .026).
Moreover, ECV correlated with total PVC beats (r = 0.387, P = .001)
and PVC burden (r = 0.401, P = .001). Post-T1 tended to be correlated
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TABLE 1 Comparison between patients with NSVT and without NSVT
NSVT group (n = 13) No NSVT group (n = 71) P value
Age, years 57.4 ± 14.5 55.9 ± 13.0 .716
Male, n (%) 7 (53.8%) 58 (81.7%) .038
Sarcomeric gene mutation, n (%) 9 (69.2%) 19 (26.8%) .005
Sarcomeric gene variant including VUS, n (%) 11 (84.6%) 36 (50.7%) .032
Thick filament mutation, n (%) 6 (46.2%) 16 (22.5%) .092
Hypertension, n (%) 5 (38.5%) 41 (57.7%) .236
Diabetes, n (%) 2 (15.4%) 14 (19.7%) >.999
FHx of SCD-first, n (%) 3 (23.1%) 4 (5.6%) .071
FHx of SCD-second, n (%) 2 (15.4%) 5 (7.0%) .589
5 y SCD risk, %* 5.01 ± 2.97 1.72 ± 0.64 .002
AF, n (%) 5 (38.5%) 8 (11.3%) .026
Total PVC beats, n 757 ± 865 73 ± 185 .015
Burden of PVC, n (%) 0.863 ± 1.044 0.078 ± 0.189 .019
The presence of PVC couplet, n (%) 8 (61.5%) 15 (21.4%) .006
Beta blocker, n (%) 10 (76.7%) 50 (70.4%) .749
Calcium channel blocker, n (%) 4 (30.8%) 23 (32.4%) >.999
ACE inhibitor, n (%) 2 (15.4%) 3 (4.2%) .169
ARB, n (%) 5 (38.5%) 33 (46.5%) .764
Echocardiographic analysis
Apical HCM, n (%) 2 (15.4%) 33 (46.5%) .063
Maximal wall thickness, mm 22.3 ± 4.2 18.9 ± 3.8 .004
LVOT or mid-LV obstruction, n (%) 4 (30.8%) 18 (25.4%) .735
LV EDV, mL 82.6 ± 25.7 70.2 ± 22.9 .082
LV ESV, mL 31.8 ± 11.2 24.3 ± 10.0 .017
LAV, mL 73.3 ± 23.0 66.4 ± 24.1 .348
LAVI, mL/m2 43.0 ± 14.1 37.2 ± 14.5 .182
LVEF, % 60.5 ± 9.3 65.0 ± 5.7 .023
E, cm/s 70.3 ± 20.1 68.6 ± 17.5 .749
A, cm/s 63.6 ± 14.6 68.1 ± 19.9 .479
DT, ms 201.3 ± 44.4 210.9 ± 58.1 .575
e0 , cm/s 4.3 ± 1.7 5.4 ± 1.8 .038
a0, cm/s 6.0 ± 1.5 8.0 ± 1.7 .001
s0 , cm/s 5.5 ± 1.6 7.2 ± 1.7 .001
E/e0 18.0 ± 7.9 13.5 ± .4.9 .066
RVSP, mmHg 29.8 ± 8.2 28.3 ± 8.3 .561
CMR analysis
LGE, n (%) 11 (84.6%) 46 (64.8%) .208
% LGE amount of LV 15.3 ± 13.2 7.0 ± 8.3 .004
Number of LGE segments in LV 5.9 ± 3.5 3.1 ± 3.1 .003
T2-average of 16-setments, ms 56.5 ± 4.8 55.8 ± 3.1 .626
Native T1-average of 16-segments, ms 1035.8 ± 51.8 1022.3 ± 48.2 .365
Post T1-average of 16-segments, ms 586.7 ± 61.4 609.1 ± 63.5 .245
ECV-average of 16-segments, % 34.2 ± 5.1 32.1 ± 4.9 .158
LVMI, g/m2 102.8 ± 24.0 85.4 ± 25.3 .024
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with PVC burden and total PVC beats (all P < .10). The optimal cutoff
value for PVC number for the presence of LGE was 45 (37.0% and
100% sensitivity and specificity, respectively) with 0.733 of the area
under the ROC curve (P = .001) (Figure 1).
3.4 | Myocardial tissue characteristics and function
between patients with higher and lower PVC burden
When we divided the patients without NSVT into two groups
according to PVC burden, the higher PVC burden group (total PVC
≥ 45, n = 17) had a tendency of more prevalent pathogenic or likely
pathogenic sarcomere-associated gene mutation (47.1% vs 20.4%,
P = .056) although it was not statistically significant, and significantly
higher prevalence of thick filament gene mutation (41.2% vs 16.7%,
P = .048) compared with the lower PVC burden group (total PVC < 45,
n = 54). In the CMR analysis, the higher PVC burden group had more
prevalent presence of LGE (100% vs 53.7%, P = .001) and higher %
LGE amount of LV (14.1 ± 11.3 vs 4.7 ± 6.1%, P = .004), number of
LGE segments (4.5 ± 2.1 vs 2.6 ± 3.2, P = .022), post-T1 (570.0 ± 62.9
vs 620.4 ± 59.6 ms, P = .006) and ECV (37.2 ± 4.8 vs 30.5 ± 3.7%,
P < .001) compared with the lower PVC burden group. PVC couplet
was more prevalent in the higher PVC burden group compared with
the lower PVC burden group (47.1% vs 13.2%, P = .006) (Table 2 and
Figure 2).
4 | DISCUSSION
This study reports on major findings with regard to ventricular
arrhythmia in HCM. First, patients with NSVT showed higher myocar-
dial fibrosis burden compared with patients without NSVT. Second,
after excluding patients who have been diagnosed with NSVT, higher
PVC burden was associated with higher %LGE and ECV, which repre-
sent myocardial extracellular space expansion. Third, a pathogenic or
probably pathogenic sarcomere-associated mutation was associated
with NSVT and higher PVC burden.
4.1 | Contribution of PVC burden and myocardial
fibrosis in HCM
Myocardial fibrosis is an NSVT substrate, and both are established risk
factors for SCD in HCM. However, contributing factors to PVC has
not yet been established in HCM. PVC arises from tissue with
increased automaticity, and it is generally considered to be a benign
phenomenon in cases without structural heart disease. However, a
recent study reported that higher prevalence of VT was induced in
PVC patients with LGE compared with patients without LGE during
programmed ventricular stimulation.11 O'Mahony C et al. reported
TABLE 1 (Continued)
NSVT group (n = 13) No NSVT group (n = 71) P value
LV EDV, mL 134.1 ± 24.7 140.6 ± 29.2 .451
LV ESV, mL 51.5 ± 19.4 49.9 ± 19.9 .792
LVEF, % 62.1 ± 10.0 65.2 ± 8.6 .244
Note: Native and post-T1 was measured in 67 patients due to poor image quality. ECV was measured in 65 patients after exclusion of six patients who
were lack of hematocrit or T1 value.
Abbreviations: ACE, angiotensin converting enzyme; AF, atrial fibrillation; ARB, angiotensin receptor blocker; CMR, cardiac magnetic resonance; FHx, fam-
ily history; ECV, extracellular volume; EDV, end-diastolic volume; EF, ejection fraction; ESV, end-systolic volume; GLS, global longitudinal strain; LAV, left
atrial volume; LAVI, left atrial volume index; LGE, late gadolinium enhancement; LV, left ventricle; LVOT, left ventricular outflow tract; MR, mitral regurgita-
tion; PVC, premature ventricular contractions; RVSP, right ventricular systolic pressure; SCD-1, sudden cardiac death of first degree; SCD-second, sudden
cardiac death of second degree; VUS, variants of uncertain significance.
F IGURE 1 A receiver operating characteristic (ROC) curve for the
presence of late gadolinium enhancement (LGE) of left ventricle. Area
under the curve for LGE is 0.733 (95% confidential interval: 0.62 to
0.85, P = .001). The optimal cutoff value for premature ventricular
complex number is 45 (37.0% and 100% sensitivity and specificity,
respectively). PVC, premature ventricular contraction
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TABLE 2 Comparison between patients according to PVC burden
Total PVC ≥ 45 (n = 17) Total PVC < 45 (n = 54) P value
Age, years 60 ± 12 55 ± 13 .133
Male, n (%) 15 (88.2%) 43 (79.6%) .502
Sarcomeric gene mutation, n (%) 8 (47.1%) 11 (20.4%) .056
Sarcomeric gene variant including VUS, n (%) 11 (30.6%) 25 (46.3%) .267
Thick filament mutation, n (%) 7 (41.2%) 9 (16.7%) .048
Hypertension, n (%) 10 (58.8%) 31 (57.4%) >.999
Diabetes, n (%) 4 (23.5%) 10 (18.5%) .730
FHx of SCD-first, n (%) 1 (5.9%) 3 (5.6%) >.999
FHx of SCD-second, n (%) 0 5 (9.3%) .328
5 y SCD risk, %* 1.63 ± 0.48 1.75 ± 0.68 .508
AF, n (%) 2 (11.8%) 6 (11.1%) >.999
The presence of PVC couplet, n (%) 8 (47.1%) 7 (13.2%) .006
Beta blocker, n (%) 10 (58.8%) 40 (74.1%) .361
Calcium channel blocker, n (%) 8 (47.1%) 15 (27.8%) .234
ACE inhibitor, n (%) 3 (17.6%) 0 .012
ARB, n (%) 10 (58.8%) 23 (42.6%) .276
Echocardiographic analysis
Apical HCM, n (%) 5 (29.4%) 28 (51.9%) .163
Maximal wall thickness, mm 19.7 ± 5.0 18.6 ± 3.3 .418
LVOT or mid-LV obstruction, n (%) 4 (23.5%) 14 (25.9%) >.999
LV EDV, mL 68.6 ± 23.1 70.7 ± 23.0 .740
LV ESV, mL 25.9 ± 14.2 23.8 ± 8.4 .445
LAV, mL 75.6 ± 33.8 63.6 ± 19.7 .072
LAVI, mL/m2 42.3 ± 19.2 35.5 ± 12.5 .091
LVEF, % 62.8 ± 6.7 65.6 ± 5.2 .068
E, cm/s 66.9 ± 13.1 69.1 ± 18.7 .674
A, cm/s 73.6 ± 25.3 66.6 ± 18.1 .248
DT, ms 211.8 ± 72.4 210.6 ± 53.8 .942
e0 , cm/s 4.7 ± 1.5 5.6 ± 1.8 .056
a0, cm/s 7.9 ± 1.7 8.1 ± 1.8 .758
s0 , cm/s 7.0 ± 1.9 7.2 ± 1.7 .693
E/e0 15.1 ± 5.4 13.0 ± 4.6 .106
RVSP, mmHg 29.8 ± 8.1 27.8 ± 4.6 .404
CMR analysis
LGE, n (%) 17 (100.0%) 29 (53.7%) .001
% LGE amount of LV 14.1 ± 11.3 4.7 ± 6.1 .004
Number of LGE segments in LV 4.5 ± 2.1 2.6 ± 3.2 .022
T2-average of 16-setments, ms 55.9 ± 3.5 55.7 ± 3.0 .825
Native T1-average of 16-segments, ms 1030.8 ± 44.8 1019.8 ± 49.3 .443
Post T1-average of 16-segments, ms 570.0 ± 62.9 620.4 ± 59.6 .006
ECV-average of 16-segments, % 37.2 ± 4.8 30.5 ± 3.7 <.001
LVMI, g/m2 88.0 ± 19.8 84.5 ± 26.9 .626
LV EDV, mL 142.2 ± 33.3 140.1 ± 28.2 .799
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that 72% of VTs were triggered by PVC, especially late-coupled PVC with
a prematurity index of >0.5 in 84% of the cases. In their study, PVC burden
on a 24-hour Holter monitoring had a tendency to determine PVC initiated
VT in HCM.12 Previous studies reported that frequent PVC was a predictor
of future VT in postinfarction patients.13,14 Therefore, although the domi-
nant mechanism is unclear, we can suggest that frequent PVC may be
associated with NSVT in HCM by triggered automaticity or re-entry forma-
tion. However, a 24-hour Holter monitoring cannot always catch the pres-
ence of NSVT; therefore, prolonged ECG monitoring is recommended
despite the inconvenience in its performance.15 In addition, previous stud-
ies revealed that PVC burden was related with SCD in the general popula-
tion.16,17 Cipriani et al. reported that exercise-induced PVC was related
with LGE in young athletes.18 Therefore, PVC burden could be a potential
risk factor for SCD in HCM patients without documented NSVT in a
24-hour Holter monitoring. In our study, PVC couplet was more frequently
seen in the NSVT and higher PVC burden groups compared with the no
NSVT and lower PVC burden groups, respectively. This finding supports
that individualized approach, such as close monitoring and strict medication
(beta-blocker), must be considered for patients with higher PVC burden. In
this study, the cutoff value of total PVC number to predict LGE was rela-
tively small at 45, which may be due to the higher prevalence of apical
HCM, which is known as relatively benign phenotype in HCM, and high
rate of beta-blocker medication.
Myocardial fibrotic regions are nonconducting and nonexciting
areas that increase the conduction heterogeneity of cardiac tissue. In
HCM, myocyte disarray and myocardial fibrosis play a critical role in the
arrhythmogenesis by promoting dispersion of electrical depolarization
and repolarization, which results in the unidirectional conduction block
and re-entry. Both fibrosis, as an abnormal substrate, and ischemia or
hypoxia, as a trigger ectopic beat or fatal ventricular arrhythmia, con-
tribute to high arrhythmic propensity in HCM.4 Consistent with previ-
ous studies, higher myocardial fibrotic burden was seen in the NSVT
group. Furthermore, higher LGE% and ECV and lower post-T1 value
were seen in the higher PVC burden group compared with the lower
PVC burden group even in the patients without NSVT in our study.
4.2 | Sarcomere mutations, PVC burden, and NSVT
in HCM
Mutations in sarcomere genes could activate proliferative and profibrotic
signals to produce pathogenic cardiac remodeling as a primary pheno-
type in HCM.19 Sarcomere-associated gene mutation may be associated
with ventricular arrhythmia due to its contribution to myocardial fibrosis,
although the results of previous studies were controversial.5,20 Our
study results also show that patients with pathogenic sarcomere muta-
tion had higher LGE amount and ECV and the patients with NSVT had
more prevalent pathogenic or likely pathogenic mutation and VUS, and a
tendency of more prevalent thick filament mutation in sarcomere genes
compared with others. After exclusion of patients with NSVT, higher
PVC burden group had a tendency of more prevalent pathogenic or
likely pathogenic sarcomere-associated mutation and significantly higher
prevalence of thick filament mutation compared with the lower PVC
burden group. It has not been clarified whether thick filament mutation
is associated with higher rate of ventricular arrhythmia in HCM.21,22 A
recent meta-analysis reported that myosin the MYH7 mutation group
showed the highest rate of ventricular arrhythmia compared with the
MYBPC3, TNNT2, and TNNI3mutation group.21
5 | LIMITATION
First, our study enrolled a relatively small number of patients. Second, the
association between PVC burden and future event of SCD and clinical
TABLE 2 (Continued)
Total PVC ≥ 45 (n = 17) Total PVC < 45 (n = 54) P value
LV ESV, mL 52.2 ± 30.3 49.2 ± 15.6 .593
LVEF, % 65.0 ± 10.3 65.2 ± 8.1 .926
Abbreviations: ACE, angiotensin converting enzyme; AF, atrial fibrillation; ARB, angiotensin receptor blocker; CMR, cardiac magnetic resonance; FHx, fam-
ily history; ECV, extracellular volume; EDV, end-diastolic volume; EF, ejection fraction; ESV, end-systolic volume; GLS, global longitudinal strain; LAV, left
atrial volume; LAVI, left atrial volume index; LGE, late gadolinium enhancement; LV, left ventricle; LVOT, left ventricular outflow tract; MR, mitral regurgita-
tion; PVC, premature ventricular contractions; RVSP, right ventricular systolic pressure; SCD-1, sudden cardiac death of first degree; SCD-second, sudden
cardiac death of second degree; VUS, variants of uncertain significance.
F IGURE 2 Comparisons of late gadolinium enhancement (LGE)
amount and global extracellular volume fraction (ECV) between
patients with higher premature ventricular complex (PVC) burden and
lower PVC burden but without nonsustained ventricular tachycardia
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outcomes could not be established. A follow-up study is needed to investi-
gate the predictive value of current PVC burden to future events.
6 | CONCLUSIONS
Total beats and PVC burden are significantly related to the increase
in myocardial fibrosis in patients with HCM but without NSVT. In the
absence of NSVT, high-PVC burden may provide information for
individualized therapy and follow-up plan to prevent fatal ventricular
arrhythmia in HCM. Moreover, the presence of sarcomere-
associated gene mutation may be also considered as one of the risk
factors for ventricular arrhythmia. Further study is needed to investi-
gate the direct relation between PVC burden and SCD in HCM.
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